SITC Cancer Immunotherapy Guideline News

Immune Monitor - March 2026

posted 4 days ago
A Message from the President One of the most impactful ways the Forward Fund supports early-career investigators is through its fellowship program . These awards provide critical funding and mentorship to help launch ...
0 comments

SITC Publishes Renal Cell Carcinoma Clinical Practice Guideline version 3.0

posted 6 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a guideline update, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal ...
0 comments

SITC Publishes Expert Insights on ICI-Related irAE Survivorship Care

posted 8 days ago
The Society for Immunotherapy of Cancer is pleased to announce the publication of a new article, “ Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: Expert insights from SITC ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

posted 8 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists ...
0 comments

JITC Digest March 2026

posted 13 days ago
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Special Series: SITC 40 th Anniversary| Popular Archive Articles Letter from the Editor Hello JITC Readers, ...
0 comments

SITC on Capitol Hill!

posted 20 days ago
On March 4, 2026, SITC proudly joined One Voice Against Cancer's (OVAC's) 2026 Lobby Day in Washington, DC, with SITC volunteer Dr. Emily Hopewell, advocating for increased funding for the National Institutes of Health (NIH), ...
0 comments

Announcing the publication of “Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles” manuscript

posted 21 days ago
The Society for Immunotherapy of Cancer (SITC) and the American Society for Transplantation and Cellular Therapy (ASTCT) are pleased to announce the publication of a comprehensive manuscript, “Advancing Cell Therapies for ...
0 comments

Oncology News Burst from the FDA: FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

posted 25 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists ...
0 comments

Immune Monitor - February 2026

posted 02-26-2026
A Message from the President The Journal for ImmunoTherapy of Cancer ( JITC ) has long been integral to SITC’s mission to advance the science and application of cancer immunotherapy . As the field continues to evolve ...
0 comments

JITC Digest February 2026

posted 02-18-2026
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC Peer Review Mentorship Program| Popular Archive Articles Letter from the Editor Hello JITC Readers, ...
0 comments

Immune Monitor - January 2026

posted 01-29-2026
A Message from the President As we begin 2026, I’m pleased to share that SITC’s 2025 Year in Review is now live. It reflects a year defined by both complexity and innovation, and highlights the scientific progress, ...
0 comments

Call for Comment: SITC Acute Leukemia CPG v2.0 Until Feb. 16

posted 01-28-2026
MANUSCRIPT TITLE: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia v2.0 Draft Manuscript Summary The Society for ...
0 comments

JITC Digest January 2026

posted 01-21-2026
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Thank You to JITC Reviewers| Popular Archive Articles Letter from the Editor Hello JITC Readers, Indeed, ...
0 comments

Immune Monitor - December 2025

posted 01-06-2026
A Message from the President As 2025 draws to a close, I am humbled by the resilience of our community. Throughout the year, many of us faced disruption in our clinics and labs with the uncertain and shifting funding ...
0 comments

JITC Digest December 2025

posted 12-17-2025
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| Popular Archive Articles Letter from the Editor Hello JITC Readers, The recent award of the Nobel Prize ...
0 comments

2025 ESMO IO Scientific Highlights

posted 12-12-2025
We are pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Immuno-Oncology Congress 2025, Dec. 10–11, 2025. Clinical and translational studies of neoadjuvant pembroluzmab ...
0 comments

SITC Hosts "AI, Upcoming Technologies, and Potential Applications: Computational Science in Immuno-oncology" Webinar

posted 12-10-2025
On December 2, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the tenth computational immuno-oncology webinar of series 5. This webinar discussed patient ...
0 comments

NEW! Myeloid Cells in Immuno-Oncology

posted 12-02-2025
Edited by Dmitry I. Gabrilovich, MD, PhD; Jennifer L. Guerriero, PhD; and Judith A. Varner, PhD The special JITC series, Myeloid Cells in Immuno-oncology, developed in collaboration with The Myeloid Network , builds ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

posted 12-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists ...
0 comments

Immune Monitor - November 2025

posted 11-25-2025
A Message from the President SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) marked a milestone for our society. We are deeply grateful to everyone who contributed to its success, including ...
0 comments

Back to SITC Cancer Immunotherapy Guidelines